Uncovering Hidden Resistances in Tuberculosis Through Targeted Genomic Sequencing
Tuberculosis (TB) remains a global health challenge, particularly in regions burdened by drug-resistant strains. A recent study examining the implementation of Targeted Next-Generation Sequencing (tNGS) in Eswatini highlights its critical role in understanding drug resistances in TB treatment. This advanced technology allows for detailed analyses of the genetic makeup of Mycobacterium tuberculosis directly from patient samples. Unlike conventional tests, tNGS offers comprehensive insights into resistance mechanisms, revealing hidden challenges in TB management.
The Problem of Unrecognized Drug Resistance
The study demonstrates a serious oversight in routine diagnostic tests, particularly regarding a problematic form of rifampicin-resistant TB, caused by the mutation rpoB I491F. Standard diagnostic procedures frequently fail to identify this mutation. This oversight results in a significant underestimation of resistance patterns and a consequent risk of inadequate treatment for affected patients.
Professor Stefan Niemann, Director of the Infection Program at the Borstel Research Center, emphasizes, “Accurate resistance diagnostics are the foundation of any successful TB treatment.” His insights underline the potential risks associated with traditional diagnostic methods, which can misclassify patients’ resistance levels, leading to ineffective therapies.
Insights from the Study: Revealing Hidden Resistances
Between June 2021 and December 2024, researchers analyzed 234 patient samples suspected of drug-resistant TB or treatment failure. The tNGS approach revealed 159 strains exhibiting rifampicin resistance. Alarmingly, nearly two-thirds of these strains carried the rpoB I491F mutation, a known “diagnostic escape” mutation that eludes detection by common testing methods.
Moreover, the findings regarding resistance to bedaquiline, a crucial drug in modern MDR-TB regimens, raised further concerns. Genetic markers linked to bedaquiline resistance were found in more than 50% of the rifampicin-resistant strains, with an alarming 85% of strains carrying the rpoB I491F mutation also resistant to bedaquiline.
Impacts on Treatment and Outcomes
The introduction of tNGS into clinical practice had immediate and profound effects on patient care. For over half of the cases with available clinical data, the sequencing results led to necessary adjustments in therapy. Remarkably, despite facing complex resistance patterns, 88% of these patients reached successful treatment outcomes.
These findings clearly indicate that many patients may receive treatment regimens containing drugs to which their infections are already resistant, emphasizing the urgent need for improved diagnostic strategies.
Implications for Global TB Control
The implications of this study stretch far beyond Eswatini. It raises fundamental questions about the reliability of routine diagnostics for drug-resistant TB. Particularly concerning is the frequent oversight of I491F-associated rifampicin resistance, heightening the risk of erroneous resistance diagnostics and ineffective treatments.
Furthermore, the co-resistance to rifampicin and bedaquiline challenges the effectiveness of standardized treatment regimens, such as BPaLM, in affected regions. Researchers advocate for the broader adoption of sequencing-based diagnostics, which may be crucial in bridging resistance gaps, minimizing treatment failures, and curbing the spread of resistant strains.
Conclusion: A Call for Enhanced Diagnostics
The experiences from Eswatini illustrate how genomic sequencing can fill significant diagnostic voids and facilitate more personalized TB care. As the world grapples with the TB epidemic, embracing advanced diagnostic technologies like tNGS could play a pivotal role in enhancing treatment efficacy and ultimately controlling the spread of drug-resistant TB globally.
Involvement of Institutions: This pioneering research involved collaboration among experts from notable institutions, including the Baylor College of Medicine Children’s Foundation Eswatini, National Tuberculosis Reference Laboratory, and others, supported by an international consortium of partners from Eswatini, Europe, and the USA.
For more information, refer to the research publication: Vambe, D., Kay, A., Ziyane, M. et al.; Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing; Nat Commun, 2026; doi: 10.1038/s41467-026-73551-w.
